# An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD

> **NCT03868566** · PHASE2 · TERMINATED · sponsor: **Sinew Pharma Inc.** · enrollment: 90 (actual)

## Conditions studied

- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** SNP-612 dose1
- **DRUG:** SNP-612 dose2

## Key facts

- **NCT ID:** NCT03868566
- **Lead sponsor:** Sinew Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-04
- **Primary completion:** 2021-09-22
- **Final completion:** 2021-10-19
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** recruitment difficulties due to Covid-19
- **Last updated:** 2023-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03868566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03868566, "An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03868566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*